Recent studies have focused on the overlap of GLP|glucose-dependent insulinotropic polypeptide|glucagon receptor activator therapies and DA signaling. While GCGR activators are widely employed for addressing type 2 T2DM, their potential consequences on reward circuits, specifically mediated by dopaminergic networks, are attracting substantial focus